|
|
Post by peppy on Oct 2, 2018 22:34:09 GMT -5
Hi Peppy, CVS owns CVS Caremark and all those CVS pharmacies. OptumRx is owned by UnitedHealthCare. Both CVS Caremark and OptumRx manage the prescription drug plans of many other companies. so the deal MNKD would need to make to get into united health is with Optum Rx? which is owned by united health. |
|
|
|
Post by nylefty on Oct 2, 2018 22:35:58 GMT -5
CVS bought Caremark to step in as a PBM and now bought Aetna to step into insurance. So now its one stop shop with pharmacies, minute clinics and claims to save patients $ and plan sponsors $ , but infact will do the opposite . you came in handy for once. I don't think the CVS-Aetna merger has been approved yet. California Insurance Commissioner Asks DOJ To Block CVS-Aetna ...
www.forbes.com/.../california-insurance-commissioner-asks-doj-to-block-cvs-a...
Aug 1, 2018 - California's Insurance Commissioner urged the U.S. Justice Department to block the merger of CVS Health and Aetna, saying it would “have ...
|
|
|
|
Post by nylefty on Oct 2, 2018 23:37:00 GMT -5
Hi Peppy, CVS owns CVS Caremark and all those CVS pharmacies. OptumRx is owned by UnitedHealthCare. Both CVS Caremark and OptumRx manage the prescription drug plans of many other companies. so the deal MNKD would need to make to get into united health is with Optum Rx? which is owned by united health. I'm not sure who would make such a deal. I do know that the GE Plan for Health drug plan, which is administered by OptumRx, covers Afrezza with a Prior Authorization requirement. |
|
|
|
Post by boca1girl on Oct 3, 2018 7:05:57 GMT -5
|
|
|
|
Post by peppy on Oct 3, 2018 7:13:38 GMT -5
The biotech industry is flourishing, yet most traders lack the tools and guidance to profit and profit consistently. Lucky for you, [name & spam message omitted by moderator].
The action in MannKind Corporation (NASDAQ:MNKD) continues to improve in recent days after the stock held key support at its 20-day exponential moving average last week on its check-down test of the $1.60/share level. One factor helping to recently flesh out the stock was the company’s announcement that Cohort 2 of the Afrezza safety and pharmacokinetics study in pediatric patients is now open for enrollment.
According to the release, “The first group of individuals participating in the ongoing pediatric study of Afrezza, which included adolescents with type 1 diabetes aged 13-17 years old, was recently completed. The study findings to date support that the single‑dose pharmacokinetic (PK) profile of insulin levels for this age group is consistent with patterns seen in adult patients. In addition, dosing over a one‑month period demonstrated a safety profile consistent with that observed in adults. As a result of these findings, MannKind and the study investigators are proceeding with enrollment of the second cohort of subjects.”
MannKind Corporation (NASDAQ:MNKD), for a little background, bills itself as a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients.
As noted above, the company offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.
The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
According to company materials, “MannKind Corporation MNKD focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza(R) (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the-art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.”
Steady as She Goes
As noted above, MNKD shares have been acting constructively in recent action, further supported by the company’s recent announcement that Cohort 2 of the Afrezza safety and pharmacokinetics study in pediatric patients is now open for enrollment.
Traders will note 69% tacked on to share pricing for the stock in the past month, a bounce that has taken root amid largely bearish action over the larger time frame. Furthermore, the company has witnessed a pop in interest, as transaction volume levels have recently pushed a bit less than 210% beyond what we have been seeing over the larger time frame.
“We are pleased to open enrollment for the next group of children and progress to the next phase of this study,” said David Kendall, M.D., Chief Medical Officer of MannKind. “As is well known, type 1 diabetes is often diagnosed in children and adolescents, and these individuals will continue to require insulin therapy throughout their lives. Evaluating the potential use of Afrezza in children and adolescents as quickly as possible is a top priority for MannKind.”
At this time, carrying a capital value in the market of $286.09M, MNKD has a significant war chest ($26.7M) of cash on the books, which must be weighed relative to about $74.9M in total current liabilities. MNKD is pulling in trailing 12-month revenues of $13.9M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 80%.
This may be a very interesting story and we will look forward to updating it again soon.
|
|
|
|
Post by barnstormer on Oct 3, 2018 7:45:32 GMT -5
Only problem with that article is the "significant war chest ($26.7M). We all know that is not significant. What will be significant is when the UT deal is done. The good news from that presentation is that there were questions being asked by analysts at the end. Unfortunaley there wasn't time. Too bad those couldn't be added on to the playback.
|
|
|
|
Post by Clement on Oct 3, 2018 9:25:42 GMT -5
The biotech industry is flourishing ..... ...........In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 80%.This may be a very interesting story and we will look forward to updating it again soon. Notice the author grossly understates revenue growth. In the Mannkind Q2 earnings call, slide 7 shows that Q2 2018 grew 142% over Q2 2017.
|
|
|
|
Post by jlaw277 on Oct 3, 2018 10:32:46 GMT -5
A few quick takeaways from Mike’s presentation after listening to it. 1. Mannkind is working with a third party to get Afrezza classified as " ultra-acting" (i.e., its own class); 2. Mannkind will receive another $30 million milestone (plus low double digits royalties) on the second drug they are currently partnering with UT; 3. For Tre-T, Mannkind will receive $25 million milestone in 2019 and another $25 million milestone in 2020. 4. Tre-T’s target market is the whole market (inhale, oral and IV) and potentially “ best in class”. 5. Recapitalization is now complete. There will be no major debt due in the next 36 months. 6. Mannkind has prioritized another four drug candidates that will be further developed in the next 12-18 months. Mike also mentioned something about a (drug) launch every one or two years as a goal towards the end of the presentation. 7. One-drop trial results will be available “ shortly”. 8. Since Mannkind signed contracts with two major PBMs in 2018, they are now working to get local coverage and remove prior-authorizations with respect to these PBMs. 9. For Afrezza, there has been consistent growth since Mannkind launch (Jan. 2017) in numbers of writers (600 to 1100), market share (among Afrezza writers from 3.2% to 4.2%) and cartridge units. 10. Note that, since Mannkind has partnered with UT for two Technosphere drug candidates, in the slide listing the five year growth drivers for the company, Mannkind has added Technosphere Platform as the foundation of the growth drivers. It appears the trial results of Tre-T were really a boost of confidence to Mannkind in their belief of the Technosphere Platform’s potential. Mike referred to the reveal of the trial results as a “flip of the cards” (and the cards turn out to be very favorable).  Question: Per item #4 above, does this mean that TreT could replace Remodulin (subcutaneous & IV), Tyvaso and Orenitram? That represents collectively $1.23 Billion in sales in 2017. A low teens royalty (12%) on net sales would equal almost $150 million per year. And that is just on UTHR's existing revenues and does not include incremental market share a Best-in-Class drug would win. I had thought that IV and subcutaneous applications of Remodulin had more to do with the functional needs (i.e. long duration) and wouldn't be applicable to the TreT inhalable option. Very exciting. |
|
|
|
Post by radgray68 on Oct 3, 2018 10:46:24 GMT -5
I absolutely love love LOVE the title "Best In Class"
|
|
|
|
Post by compound26 on Oct 3, 2018 11:10:29 GMT -5
A few quick takeaways from Mike’s presentation after listening to it. 1. Mannkind is working with a third party to get Afrezza classified as " ultra-acting" (i.e., its own class); 2. Mannkind will receive another $30 million milestone (plus low double digits royalties) on the second drug they are currently partnering with UT; 3. For Tre-T, Mannkind will receive $25 million milestone in 2019 and another $25 million milestone in 2020. 4. Tre-T’s target market is the whole market (inhale, oral and IV) and potentially “ best in class”. 5. Recapitalization is now complete. There will be no major debt due in the next 36 months. 6. Mannkind has prioritized another four drug candidates that will be further developed in the next 12-18 months. Mike also mentioned something about a (drug) launch every one or two years as a goal towards the end of the presentation. 7. One-drop trial results will be available “ shortly”. 8. Since Mannkind signed contracts with two major PBMs in 2018, they are now working to get local coverage and remove prior-authorizations with respect to these PBMs. 9. For Afrezza, there has been consistent growth since Mannkind launch (Jan. 2017) in numbers of writers (600 to 1100), market share (among Afrezza writers from 3.2% to 4.2%) and cartridge units. 10. Note that, since Mannkind has partnered with UT for two Technosphere drug candidates, in the slide listing the five year growth drivers for the company, Mannkind has added Technosphere Platform as the foundation of the growth drivers. It appears the trial results of Tre-T were really a boost of confidence to Mannkind in their belief of the Technosphere Platform’s potential. Mike referred to the reveal of the trial results as a “flip of the cards” (and the cards turn out to be very favorable).
That represents collectively $1.23 Billion in sales in 2017. A low teens royalty (12%) on net sales would equal almost $150 million per year. And that is just on UTHR's existing revenues and does not include incremental market share a Best-in-Class drug would win. I had thought that IV and subcutaneous applications of Remodulin had more to do with the functional needs (i.e. long duration) and wouldn't be applicable to the TreT inhalable option. Very exciting. Yes, that is my impression from listening to what Mike said in his presentation. Mike actually specifically mentioned how much annual sales each of these products generates. I think that makes sense as all of these different products are actually based on the same active ingredient (Treprostinil, which also forms the basis of Tre-T), with the main differences among them being how they are administered. This article ( A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration) provides a brief summary and comparison of these products. Interestingly, $150 million per year (for Mannkind) is also the number I have in my mind. I think that is a realistic number if Tre-T indeed turns out to be "best-in-class". In this video, Martine Rothblatt noted that the annual revenue of the PAH drugs of UT is about $1.5 billion and that UT is paying $150 million royalty annually to GSK (because UT originally got the prototype of the PAH drugs from GSK for $25,000 + a 10% royalty). Talking about investment returns of GSK on this! |
|
|
|
Post by brotherm1 on Oct 3, 2018 12:22:28 GMT -5
brotherm1 upgrades MNKD from buy to powerful as a locomotive buy
|
|
|
|
Post by mango on Oct 3, 2018 12:35:07 GMT -5
The biotech industry is flourishing ..... ...........In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 80%.This may be a very interesting story and we will look forward to updating it again soon. Notice the author grossly understates revenue growth. In the Mannkind Q2 earnings call, slide 7 shows that Q2 2018 grew 142% over Q2 2017.
Why did the author of the article publish false information? Who is the author? |
|
|
|
Post by mango on Oct 3, 2018 12:52:03 GMT -5
A few quick takeaways from Mike’s presentation after listening to it. 1. Mannkind is working with a third party to get Afrezza classified as " ultra-acting" (i.e., its own class); 2. Mannkind will receive another $30 million milestone (plus low double digits royalties) on the second drug they are currently partnering with UT; 3. For Tre-T, Mannkind will receive $25 million milestone in 2019 and another $25 million milestone in 2020. 4. Tre-T’s target market is the whole market (inhale, oral and IV) and potentially “ best in class”. 5. Recapitalization is now complete. There will be no major debt due in the next 36 months. 6. Mannkind has prioritized another four drug candidates that will be further developed in the next 12-18 months. Mike also mentioned something about a (drug) launch every one or two years as a goal towards the end of the presentation. 7. One-drop trial results will be available “ shortly”. 8. Since Mannkind signed contracts with two major PBMs in 2018, they are now working to get local coverage and remove prior-authorizations with respect to these PBMs. 9. For Afrezza, there has been consistent growth since Mannkind launch (Jan. 2017) in numbers of writers (600 to 1100), market share (among Afrezza writers from 3.2% to 4.2%) and cartridge units. 10. Note that, since Mannkind has partnered with UT for two Technosphere drug candidates, in the slide listing the five year growth drivers for the company, Mannkind has added Technosphere Platform as the foundation of the growth drivers. It appears the trial results of Tre-T were really a boost of confidence to Mannkind in their belief of the Technosphere Platform’s potential. Mike referred to the reveal of the trial results as a “flip of the cards” (and the cards turn out to be very favorable). Wow. (Have not seen presentation yet) |
|
|
|
Post by Clement on Oct 3, 2018 12:59:36 GMT -5
Notice the author grossly understates revenue growth. In the Mannkind Q2 earnings call, slide 7 shows that Q2 2018 grew 142% over Q2 2017.
Why did the author of the article publish false information? Who is the author? I went to the url (from boca above) and the author is "Staff FDA Headlines". |
|
|
|
Post by mnholdem on Oct 3, 2018 13:14:05 GMT -5
brotherm1 upgrades MNKD from buy to powerful as a locomotive buy Able to leap tall resistance bands?
|
|
